Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.64 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.49 |
| ▸ | TYMS | P04818 | 4/20 | 0.49 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12918449 | 1.00 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL13153886 | 1.00 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL26757491 | 1.00 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL6034461 | 0.89 | DUT (0.66) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL140597 | 0.89 | DUT (0.66) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL16571519 | 0.88 | DUT (0.52) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL1744123 | 0.88 | DUT (0.62) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL516165 | 0.88 | DUT (0.62) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL2009956 | 0.88 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL2056624 | 0.88 | DUT (0.64) | DUTP2RY2P2RY4P2RY6TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2584947-B2 | — | — | 1997-02-26 | — | — | JP | claimed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | claimed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | claimed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | claimed |
| WO-2025101722-A1 | HIGH-AFFINITY ENGINEERED CHROMODOMAINS | AXOIYA INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025064811-A1 | DNA-DEPENDENT DNA POLYMERASE COMPOSITIONS, METHODS, AND USES THEREOF | REVISION BIO CORPORATION (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025064825-A1 | DNA LIGASE COMPOSITIONS, METHODS, AND USES THEREOF | REVISION BIO CORPORATION (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-3044228-B1 | HIGHLY EFFICIENT SYNTHESIS OF LONG RNA USING REVERSE DIRECTION APPROACH | CHEMGENES CORP (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10167308-B2 | Highly efficient synthesis of long RNA using reverse direction approach | CHEMGENES CORPORATION (US) | 2019-01-01 | — | — | US | disclosed |
| US-9969764-B2 | Dithiolane functionalized nucleoside amidites and supports for stronger immobilization of bio-molecules on solid surfaces | CHEMGENES CORPORATION | 2018-05-15 | — | — | US | disclosed |
| US-9884885-B2 | Synthesis of labile base protected-modified deoxy and modified ribo nucleosides, corresponding phosphoramidites and supports and their use in high purity oligonucleotide synthesis | CHEMGENES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| EP-0831849-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167308-B2 | Highly efficient synthesis of long RNA using reverse direction approach | NSUN3, POLRMT, METTL16 | DUT 162/4885P2RY2 4653/4885P2RY4 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.